LKFT
Lakefront Biotherapeutics NV trades as LKFT and has a market capitalization of $1.85 B, making it the #2151 largest US-listed company by market value. This page tracks Lakefront Biotherapeutics NV through 511 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| 6-K | - | 2026-05-27 |
| 424B3 | - | 2026-05-08 |
| 6-K | - | 2026-05-06 |
| 6-K | - | 2026-04-29 |
| 6-K | - | 2026-03-31 |
| 6-K | - | 2026-03-30 |
| 20-F | - | 2026-03-26 |
| 6-K | - | 2026-03-24 |
Lakefront Receives Transparency Notification from Bank of America
Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update
Galapagos’ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders’ Meetings 2026
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - Lakefront Biotherapeutics
Galapagos Announces Nomination of Gino Santini to its Board of Directors - Lakefront Biotherapeutics
The largest companies sharing Lakefront Biotherapeutics NV's SEC industry classification (pharmaceutical preparations).
Lakefront Biotherapeutics NV (LKFT) has a market capitalization of $1.85 B as of 2026-05-29, ranking #2151 among US-listed companies.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.